CASI is dedicated to the development and delivery of high-quality pharmaceutical products and innovative therapeutics to patients worldwide while targeting the China market. We are focused on acquiring, licensing, developing and commercializing products that address areas of unmet medical need. We intend to execute our plan to become the leading platform to launch medicines in the greater China market leveraging our China-based regulatory and commercial competencies and our global drug development expertise.
CASI offers the following value drivers:
- Acquisition of Approved Products for Commercialization in greater China
Market - Well-positioned to pursue significant and unprecedented market opportunities in China and potential segments worldwide.
Model - Compelling business model with important U.S./China synergies and competitive advantage with efficiency and effectiveness for drug development and commercialization.
Product - A strong and growing product pipeline developed strategically for significant commercial opportunity in greater China.
Management - An experienced, motivated leadership team with a track record of accomplishment in both China and the U.S.
Finance - Strong cash position, backed by successful venture fund and smart money, under careful financial management with low burn rate.
Value Drivers - Significant defined near-term value drivers supporting long-term growth.
Annual Stockholders Meeting Notice and Proxy
June 20, 2019
Download proxy & meeting materials
Safe Harbor Information
Our forward-looking statements are based on information available to us today, and we will not update these statements.
Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility in the market price of our common stock; risks relating to interests of our largest stockholders that differ from our other stockholders; the risk of substantial dilution of existing stockholders in future stock issuances; the difficulty of executing our business strategy in China; our inability to predict when or if our product candidates will be approved for marketing by the China Food and Drug Administration authorities; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; risks associated with our product candidates; risks associated with any early-stage products under development; the risk that results in preclinical and early clinical models are not necessarily indicative of later clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks). Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission, or the SEC, which are available at www.sec.gov.